{
  "id": 10981747,
  "title": "Lilly's EloraTZP Delivers Weight Loss Results In Phase 2b Trial",
  "url": "https://urgent.news/2026/09/30/lillys-eloratzp-delivers-weight-loss-results-in-phase-2b-trial",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-30T15:15:23.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/lillys-eloratzp-delivers-weight-loss-results-phase-2b-trial"
  },
  "original_language": "en",
  "account": null,
  "summary": "(RTTNews) - Eli Lilly and Company (LLY) said on Wednesday that its investigational EloraTZP combination of eloralintide and tirzepatide delivered substantial weight loss and reductions in blood sugar levels in a Phase 2b trial involving 367 adults with obesity or overweight and t",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}